Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05921149 · ClinicalTrials.gov registry record · NA
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
A NA study, sponsored by Endeavor Health.
- Not yet
- Registry status
- NA
- Development phase
- 170
- Enrollment target
NCT05921149 is a NA study that has not yet begun recruiting, run by Endeavor Health. The registered enrollment target is 170 participants.
The verdict
NCT05921149, a NA study, has not yet begun recruiting, sponsored by Endeavor Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
Study Summary
Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed. Short term fasting protects against toxic effects of chemotherapy without decreasing efficacy. In a prospective clinical trial of breast cancer patients randomized to FMD or regular diet during chemotherapy, less antiemetic was required in the FMD group; radiographic and pathologic responses were better in this group. This trial tests whether platinum-taxane chemotherapy combined with a FMD in advanced and recurrent ovarian, fallopian tube and primary peritoneal cancer patients is associated with decreased toxicity and/ or improved tumor response to therapy.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DIETARY_SUPPLEMENT Fasting Mimicking Diet (Xentigen by L'Nutra)
- DIETARY_SUPPLEMENT Standard diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2024-05-25 |
| Est. Completion | 2031-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05921149
The ClinicalTrials.gov registry entry for NCT05921149 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT05921149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05921149 about?
NCT05921149 is a clinical study titled "Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer". Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed. Short term fasting protects against toxic effects of chemotherapy without decreasing efficacy. In a prospective clinical trial of breast cancer patients randomized to ...
What is the current status of trial NCT05921149?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2024-05-25. Estimated completion is 2031-06-01.
What interventions are being tested in trial NCT05921149?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Fasting Mimicking Diet (Xentigen by L'Nutra) (DIETARY_SUPPLEMENT), Standard diet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05921149?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.